CYTOMX THERAPEUTICS INC (CTMX) Stock Price, Quote, News and Overview
NASDAQ:CTMX - Nasdaq - US23284F1057 - Common Stock - Currency: USD
CTMX Quote, Performance and Key Statistics
NASDAQ:CTMX (2/21/2025, 8:11:15 PM)
0.78
-0.04 (-4.42%)
The current stock price of CTMX is 0.78 USD. In the past month the price decreased by -10.12%. In the past year, price decreased by -48%.
CTMX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CTMX
Company Profile
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2015-10-08. The company is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
Company Info
CYTOMX THERAPEUTICS INC
151 Oyster Point Blvd., Suite 400
South San Francisco CALIFORNIA 94080 US
CEO: Sean A. McCarthy
Employees: 121
Company Website: https://cytomx.com/
Investor Relations: https://ir.cytomx.com
Phone: 16505153185
CYTOMX THERAPEUTICS INC / CTMX FAQ
What is the stock price of CYTOMX THERAPEUTICS INC today?
The current stock price of CTMX is 0.78 USD. The price decreased by -4.42% in the last trading session.
What is the ticker symbol for CYTOMX THERAPEUTICS INC stock?
The exchange symbol of CYTOMX THERAPEUTICS INC is CTMX and it is listed on the Nasdaq exchange.
On which exchange is CTMX stock listed?
CTMX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CYTOMX THERAPEUTICS INC stock?
13 analysts have analysed CTMX and the average price target is 4.78 USD. This implies a price increase of 512.78% is expected in the next year compared to the current price of 0.78. Check the CYTOMX THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CYTOMX THERAPEUTICS INC worth?
CYTOMX THERAPEUTICS INC (CTMX) has a market capitalization of 61.04M USD. This makes CTMX a Micro Cap stock.
How many employees does CYTOMX THERAPEUTICS INC have?
CYTOMX THERAPEUTICS INC (CTMX) currently has 121 employees.
What are the support and resistance levels for CYTOMX THERAPEUTICS INC (CTMX) stock?
CYTOMX THERAPEUTICS INC (CTMX) has a resistance level at 0.82. Check the full technical report for a detailed analysis of CTMX support and resistance levels.
Is CYTOMX THERAPEUTICS INC (CTMX) expected to grow?
The Revenue of CYTOMX THERAPEUTICS INC (CTMX) is expected to grow by 27.18% in the next year. Check the estimates tab for more information on the CTMX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CYTOMX THERAPEUTICS INC (CTMX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CTMX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CTMX, evaluating the profitability, health, valuation and growth aspects
- CYTOMX THERAPEUTICS INC (CTMX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CYTOMX THERAPEUTICS INC (CTMX) Sales and EPS estimates to see what analysts future expectations are.
- CYTOMX THERAPEUTICS INC (CTMX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CYTOMX THERAPEUTICS INC (CTMX) Insider and Institutional Ownership to learn about the owners and their transactions.
- CYTOMX THERAPEUTICS INC (CTMX) Stock Chart to make your own analysis
- CYTOMX THERAPEUTICS INC (CTMX) Latest news and press-releases to stay up to date.
Does CYTOMX THERAPEUTICS INC (CTMX) stock pay dividends?
CTMX does not pay a dividend.
When does CYTOMX THERAPEUTICS INC (CTMX) report earnings?
CYTOMX THERAPEUTICS INC (CTMX) will report earnings on 2025-02-26, after the market close.
What is the Price/Earnings (PE) ratio of CYTOMX THERAPEUTICS INC (CTMX)?
The PE ratio for CYTOMX THERAPEUTICS INC (CTMX) is 4.59. This is based on the reported non-GAAP earnings per share of 0.17 and the current share price of 0.78 USD. Check the full fundamental report for a full analysis of the valuation metrics for CTMX.
What is the Short Interest ratio of CYTOMX THERAPEUTICS INC (CTMX) stock?
The outstanding short interest for CYTOMX THERAPEUTICS INC (CTMX) is 5.94% of its float. Check the ownership tab for more information on the CTMX short interest.
CTMX Technical Analysis
CTMX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CTMX. CTMX has a bad profitability rating. Also its financial health evaluation is rather negative.
CTMX Financial Highlights
Over the last trailing twelve months CTMX reported a non-GAAP Earnings per Share(EPS) of 0.17. The EPS increased by 136.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.92% | ||
| ROA | 9.95% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CTMX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CTMX. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of -118.59% and a revenue growth 27.18% for CTMX